{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:06:42Z","timestamp":1787026002715,"version":"build-2736575974"},"reference-count":118,"publisher":"National Institute for Health and Care Research","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["16\/154\/01"],"award-info":[{"award-number":["16\/154\/01"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n There are limited options currently recommended in National Institute for Health and Care Excellence guidelines for the treatment of bipolar depression. Pramipexole has been shown to improve mood symptoms in two small pilot studies in such patients.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n Primary: to evaluate the clinical effectiveness of pramipexole versus placebo alongside routine mood-stabilising medications over 12 weeks in patients with treatment-resistant bipolar depression. Secondary: evaluate the impact of pramipexole on mood and anxiety, psychosocial function, cost-effectiveness, and safety and tolerability over 48 weeks.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Multicentre, randomised, placebo-controlled trial of pramipexole versus placebo in addition to standard-of-care mood stabilisers. Clinicians, researchers and participants were blinded throughout the duration of the study. Pre-randomisation stage (to adjust antipsychotics or commence mood stabilisers where required) before randomisation. Weekly online assessments of mood and anxiety from randomisation to week 52, with psychosocial function, quality of life and healthcare resource utilisation assessments conducted at regular intervals.<\/jats:p>\n <\/jats:sec>\n \n Setting<\/jats:title>\n Twenty-one National Health Service trusts and Health Boards across England and Scotland.<\/jats:p>\n <\/jats:sec>\n \n Participants<\/jats:title>\n Patients aged 18 years and over with a diagnosis of treatment-resistant bipolar depression currently under secondary care mental health services. Aim to randomise 290 participants.<\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Pramipexole or matched placebo orally once daily, titrated from 0.25\u00a0mg to maximum of 2.5\u00a0mg (salt weight) depending on efficacy and tolerability.<\/jats:p>\n <\/jats:sec>\n \n Main outcome measures<\/jats:title>\n Depression \u2013 Quick Inventory for Depressive Symptomology; anxiety \u2013 Generalised Anxiety Disorder-7-item scale; psychosocial functioning \u2013 Work and Social Adjustment Scale; hypomania\/mania \u2013 Altman Self-rating Scale of Mania; tolerability \u2013 Treatment Satisfaction Questionnaire for Medication; well-being and quality of life \u2013 EuroQol-5 Dimensions, five-level version, ICEpop CAPability measure for Adults and Oxford CAPabilities questionnaire-Mental Health tools.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Thirty-nine participants randomised (18 to pramipexole and 21 to placebo) with 36 providing data for the primary analysis. Pramipexole led to greater reductions in depressive symptoms at 12 weeks compared to placebo [4.4 (4.8) vs. 2.1 (5.1)]: a medium-sized (\n d<\/jats:italic>\n \u00a0=\u00a0\u22120.72) but not statistically significant difference (95% confidence interval \u22120.4 to 6.3;\n p<\/jats:italic>\n \u00a0=\u00a00.087). There were some statistically significant positive effects of pramipexole on secondary outcomes (reduction in depressive symptoms at 36 weeks, response and remission rates at trial exit, psychosocial function). Pramipexole was associated with an increased rate of hypomania\/manic symptoms, but this appeared to be reduced by coadministration with an antipsychotic. General tolerability of pramipexole was good. There were significant annual gains in health-related quality of life and capability-well-being and tendency towards reduced health and social care costs.\n <\/jats:p>\n <\/jats:sec>\n \n Limitations<\/jats:title>\n Small sample size and variable follow-up period due to recruitment during COVID-19 pandemic and the trial closing early. Participants limited to those in secondary care mental health services. All assessments only available in English.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n No change in clinical practice can be recommended as there was not a significant difference between pramipexole and placebo on the primary efficacy outcome measure. However, there was evidence of positive effects of pramipexole on mood, psychosocial function and quality of life.<\/jats:p>\n <\/jats:sec>\n \n Future work<\/jats:title>\n Replication in a larger population and research to investigate the impact of coadministration of antipsychotics alongside pramipexole.<\/jats:p>\n <\/jats:sec>\n \n Trial registration<\/jats:title>\n This trial is registered as ISRCTN72151939 and EudraCT 2018-2869-18.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n \n This award was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme (NIHR award ref: 16\/154\/01) and is published in full in\n Health Technology Assessment<\/jats:italic>\n ; Vol. 29, No. 21. See the NIHR Funding and Awards website for further award information.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hbfc1953","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T08:00:38Z","timestamp":1725955238000},"page":"1-216","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Pramipexole in addition to mood stabilisers for treatment-resistant bipolar depression: the PAX-BD randomised double-blind placebo-controlled trial"],"prefix":"10.3310","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9966-1834","authenticated-orcid":true,"given":"Hamish","family":"McAllister-Williams","sequence":"first","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1211-936X","authenticated-orcid":true,"given":"Nicola","family":"Goudie","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3094-5366","authenticated-orcid":true,"given":"Lumbini","family":"Azim","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8206-5016","authenticated-orcid":true,"given":"Victoria","family":"Bartle","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1183-8410","authenticated-orcid":true,"given":"Michael","family":"Berger","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1696-1506","authenticated-orcid":true,"given":"Chrissie","family":"Butcher","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-0302","authenticated-orcid":true,"given":"Thomas","family":"Chadwick","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4168-9185","authenticated-orcid":true,"given":"Emily","family":"Clare","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4147-4846","authenticated-orcid":true,"given":"Paul","family":"Courtney","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8351-7060","authenticated-orcid":true,"given":"Lyndsey","family":"Dixon","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5340-6931","authenticated-orcid":true,"given":"Nichola","family":"Duffelen","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2292-0495","authenticated-orcid":true,"given":"Tony","family":"Fouweather","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3395-8250","authenticated-orcid":true,"given":"William","family":"Gann","sequence":"additional","affiliation":[{"name":"Sheffield Health and Social Care NHS Foundation Trust, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5281-5960","authenticated-orcid":true,"given":"John","family":"Geddes","sequence":"additional","affiliation":[{"name":"University of Oxford, Oxford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1586-5069","authenticated-orcid":true,"given":"Sumeet","family":"Gupta","sequence":"additional","affiliation":[{"name":"Tees, Esk and Wear Valleys NHS Foundation Trust, Darlington, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5812-3121","authenticated-orcid":true,"given":"Beth","family":"Hall","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2696-2553","authenticated-orcid":true,"given":"Timea","family":"Helter","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8775-3600","authenticated-orcid":true,"given":"Paul","family":"Hindmarch","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3027-9052","authenticated-orcid":true,"given":"Eva-Maria","family":"Holstein","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9563-7754","authenticated-orcid":true,"given":"Ward","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Surrey and Borders Partnership NHS Trust, Leatherhead, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2056-5047","authenticated-orcid":true,"given":"Phil","family":"Mawson","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5760-9824","authenticated-orcid":true,"given":"Iain","family":"McKinnon","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5656-5647","authenticated-orcid":true,"given":"Adam","family":"Milne","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0078-4787","authenticated-orcid":true,"given":"Aisling","family":"Molloy","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8293-0732","authenticated-orcid":true,"given":"Abigail","family":"Moore","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2910-4121","authenticated-orcid":true,"given":"Richard","family":"Morriss","sequence":"additional","affiliation":[{"name":"University of Nottingham, Nottingham, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0659-6971","authenticated-orcid":true,"given":"Anisha","family":"Nakulan","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9279-8627","authenticated-orcid":true,"given":"Judit","family":"Simon","sequence":"additional","affiliation":[{"name":"Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2267-1951","authenticated-orcid":true,"given":"Daniel","family":"Smith","sequence":"additional","affiliation":[{"name":"Edinburgh University, Edinburgh, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7265-6223","authenticated-orcid":true,"given":"Bryony","family":"Stokes-Crossley","sequence":"additional","affiliation":[{"name":"Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2274-8330","authenticated-orcid":true,"given":"Paul","family":"Stokes","sequence":"additional","affiliation":[{"name":"King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7770-7341","authenticated-orcid":true,"given":"Andrew","family":"Swain","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1253-6668","authenticated-orcid":true,"given":"Zo\u00eb","family":"Walmsley","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6372-0393","authenticated-orcid":true,"given":"Christopher","family":"Weetman","sequence":"additional","affiliation":[{"name":"Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2291-6952","authenticated-orcid":true,"given":"Allan H","family":"Young","sequence":"additional","affiliation":[{"name":"King\u2019s College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2558-3367","authenticated-orcid":true,"given":"Stuart","family":"Watson","sequence":"additional","affiliation":[{"name":"Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2025,5]]},"reference":[{"key":"key2025060220293600_ref1-bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1590\/1516-4446-2012-1693","article-title":"Bipolar disorder prevalence: a systematic review and meta-analysis of the literature","volume":"37","author":"Clemente","year":"2015","journal-title":"Braz J Psychiatry"},{"key":"key2025060220293600_ref2-bib2","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/bdi.12296","article-title":"Life expectancy in bipolar disorder","volume":"17","author":"Kessing","year":"2015","journal-title":"Bipolar Disord"},{"key":"key2025060220293600_ref4-bib4","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","article-title":"The long-term natural history of the weekly symptomatic status of bipolar I disorder","volume":"59","author":"Judd","year":"2002","journal-title":"Arch Gen Psychiatry"},{"key":"key2025060220293600_ref5-bib5","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/archpsyc.60.3.261","article-title":"A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder","volume":"60","author":"Judd","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"key2025060220293600_ref6-bib6","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","article-title":"A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression","volume":"162","author":"Calabrese","year":"2005","journal-title":"Am J Psychiatry"},{"key":"key2025060220293600_ref7-bib7","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","article-title":"Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression","volume":"60","author":"Tohen","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"key2025060220293600_ref8-bib8","unstructured":"Prescribing Observatory for Mental Health. Topic 15a Baseline Audit Report. Prescribing Valproate for Bipolar Disorder. 2016."},{"key":"key2025060220293600_ref9-bib9","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1017\/S0924270800035547","article-title":"Stabilization in the treatment of mania, depression and mixed states","volume":"12","author":"Kupfer","year":"2000","journal-title":"Acta Neuropsychiatr"},{"key":"key2025060220293600_ref10-bib10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/0269881116636545","article-title":"Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology","volume":"30","author":"Goodwin","year":"2016","journal-title":"J Psychopharmacol"},{"key":"key2025060220293600_ref11-bib11","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1007\/BF02245568","article-title":"Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole","volume":"115","author":"Willner","year":"1994","journal-title":"Psychopharmacology (Berl)"},{"key":"key2025060220293600_ref12-bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00210-009-0405-0","article-title":"Effects of pramipexole on the duration of immobility during the forced swim test in normal and ACTH-treated rats","volume":"380","author":"Kitagawa","year":"2009","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"key2025060220293600_ref13-bib13","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2015.03.020","article-title":"Long-term treatment with L-DOPA or pramipexole affects adult neurogenesis and corresponding non-motor behavior in a mouse model of Parkinson\u2019s disease","volume":"95","author":"Chiu","year":"2015","journal-title":"Neuropharmacology"},{"key":"key2025060220293600_ref14-bib14","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.ejphar.2009.06.029","article-title":"Antidepressant effects of pramipexole, a dopamine D3\/D2 receptor agonist, and 7-OH-DPAT, a dopamine D3 receptor agonist, in olfactory bulbectomized rats","volume":"616","author":"Breuer","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"key2025060220293600_ref15-bib15","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/S0893-133X(01)00358-X","article-title":"Regulation of adult neurogenesis by antidepressant treatment","volume":"25","author":"Duman","year":"2001","journal-title":"Neuropsychopharmacology"},{"key":"key2025060220293600_ref16-bib16","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.2174\/1871527313666141130223723","article-title":"Hippocampal neurogenesis, neurotrophic factors and depression: possible therapeutic targets?","volume":"13","author":"Serafini","year":"2014","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"key2025060220293600_ref17-bib17","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/ene.13303","article-title":"Efficacy and safety of pramipexole extended-release in Parkinson\u2019s disease: a review based on meta-analysis of randomized controlled trials","volume":"24","author":"Shen","year":"2017","journal-title":"Eur J Neurol"},{"key":"key2025060220293600_ref18-bib18","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clinthera.2009.01.012","article-title":"The effect of pramipexole on mood and motivational symptoms in Parkinson\u2019s disease: a meta-analysis of placebo-controlled studies","volume":"31","author":"Leentjens","year":"2009","journal-title":"Clin Ther"},{"key":"key2025060220293600_ref19-bib19","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S1474-4422(10)70106-X","article-title":"Pramipexole for the treatment of depressive symptoms in patients with Parkinson\u2019s disease: a randomised, double-blind, placebo-controlled trial","volume":"9","author":"Barone","year":"2010","journal-title":"Lancet Neurol"},{"key":"key2025060220293600_ref20-bib20","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/mp.2017.16","article-title":"The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment","volume":"22","author":"Ashok","year":"2017","journal-title":"Mol Psychiatry"},{"key":"key2025060220293600_ref21-bib21","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3109\/10401230009147102","article-title":"Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review","volume":"12","author":"Sporn","year":"2000","journal-title":"Ann Clin Psychiatry"},{"key":"key2025060220293600_ref22-bib22","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1055\/s-2001-15872","article-title":"Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series","volume":"34","author":"Perugi","year":"2001","journal-title":"Pharmacopsychiatry"},{"key":"key2025060220293600_ref23-bib23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1034\/j.1399-5618.2002.01171.x","article-title":"Pramipexole in treatment-resistant depression: a 16-week naturalistic study","volume":"4","author":"Lattanzi","year":"2002","journal-title":"Bipolar Disord"},{"key":"key2025060220293600_ref24-bib24","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s11126-010-9130-6","article-title":"Long-term use of pramipexole in bipolar depression: a naturalistic retrospective chart review","volume":"81","author":"El-Mallakh","year":"2010","journal-title":"Psychiatr Q"},{"key":"key2025060220293600_ref25-bib25","doi-asserted-by":"crossref","first-page":"372474","DOI":"10.1100\/2012\/372474","article-title":"The efficacy of pramipexole, a dopamine receptor agonist, as an adjunctive treatment in treatment-resistant depression: an open-label trial","volume":"2012","author":"Hori","year":"2012","journal-title":"ScientificWorldJournal"},{"key":"key2025060220293600_ref26-bib26","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.jad.2012.11.030","article-title":"Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder","volume":"150","author":"Dell\u2019osso","year":"2013","journal-title":"J Affect Disord"},{"key":"key2025060220293600_ref27-bib27","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1176\/appi.ajp.2015.15060788","article-title":"Clinical experience with high-dosage pramipexole in patients with treatment-resistant depressive episodes in unipolar and bipolar depression","volume":"173","author":"Fawcett","year":"2016","journal-title":"Am J Psychiatry"},{"key":"key2025060220293600_ref28-bib28","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1176\/appi.ajp.161.3.564","article-title":"Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression","volume":"161","author":"Goldberg","year":"2004","journal-title":"Am J Psychiatry"},{"key":"key2025060220293600_ref29-bib29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.biopsych.2004.03.013","article-title":"Pramipexole for bipolar II depression: a placebo-controlled proof of concept study","volume":"56","author":"Zarate","year":"2004","journal-title":"Biol Psychiatry"},{"key":"key2025060220293600_ref30-bib30","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1517\/14728222.10.4.515","article-title":"Targeting the dopamine D2 receptor in schizophrenia","volume":"10","author":"Seeman","year":"2006","journal-title":"Expert Opin Ther Targets"},{"key":"key2025060220293600_ref31-bib31","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.clinthera.2006.08.004","article-title":"A review of the receptor-binding and pharmacokinetic properties of dopamine agonists","volume":"28","author":"Kvernmo","year":"2006","journal-title":"Clin Ther"},{"key":"key2025060220293600_ref32-bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0922-4106(95)90013-6","article-title":"Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors","volume":"290","author":"Mierau","year":"1995","journal-title":"Eur J Pharmacol"},{"key":"key2025060220293600_ref33-bib33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.nicl.2016.06.007","article-title":"Occupancy of pramipexole (Sifrol) at cerebral dopamine D2\/3 receptors in Parkinson\u2019s disease patients","volume":"12","author":"Deutschlander","year":"2016","journal-title":"Neuroimage Clin"},{"key":"key2025060220293600_ref34-bib34","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1460-9568.1993.tb00480.x","article-title":"Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography","volume":"5","author":"Landwehrmeyer","year":"1993","journal-title":"Eur J Neurosci"},{"key":"key2025060220293600_ref35-bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/0166-4328(93)90113-5","article-title":"Differential effects of excitotoxic lesions of the basolateral amygdala, ventral subiculum and medial prefrontal cortex on responding with conditioned reinforcement and locomotor activity potentiated by intra-accumbens infusions of D-amphetamine","volume":"55","author":"Burns","year":"1993","journal-title":"Behav Brain Res"},{"key":"key2025060220293600_ref36-bib36","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/S0959-4388(96)80077-8","article-title":"Neurobehavioural mechanisms of reward and motivation","volume":"6","author":"Robbins","year":"1996","journal-title":"Curr Opin Neurobiol"},{"key":"key2025060220293600_ref37-bib37","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1177\/0269881118756059","article-title":"Reward motivation in humans and its relationship to dopamine D(2\/3) receptor availability: a pilot study with dual [(11)C]-raclopride and [(11)C]-(+)-PHNO imaging","volume":"32","author":"Caravaggio","year":"2018","journal-title":"J Psychopharmacol"},{"key":"key2025060220293600_ref38-bib38","doi-asserted-by":"crossref","first-page":"4196961","DOI":"10.1155\/2018\/4196961","article-title":"Ropinirole and pramipexole promote structural plasticity in human iPSC-derived dopaminergic neurons via BDNF and mTOR signaling","volume":"2018","author":"Collo","year":"2018","journal-title":"Neural Plast"},{"key":"key2025060220293600_ref39-bib39","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/sj.npp.1301574","article-title":"Stress, depression, and neuroplasticity: a convergence of mechanisms","volume":"33","author":"Pittenger","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"key2025060220293600_ref40-bib40","doi-asserted-by":"crossref","first-page":"723915","DOI":"10.1155\/2014\/723915","article-title":"Hippocampal neurogenesis and antidepressive therapy: shocking relations","volume":"2014","author":"Rotheneichner","year":"2014","journal-title":"Neural Plast"},{"key":"key2025060220293600_ref41-bib41","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1007\/s00213-018-4950-4","article-title":"Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression","volume":"235","author":"Levy","year":"2018","journal-title":"Psychopharmacology"},{"key":"key2025060220293600_ref42-bib42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.neubiorev.2019.09.040","article-title":"Physical activity and depression: towards understanding the antidepressant mechanisms of physical activity","volume":"107","author":"Kandola","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"key2025060220293600_ref43-bib43","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/ijnp\/pyy005","article-title":"The dopamine receptor D3 regulates lipopolysaccharide-induced depressive-like behavior in mice","volume":"21","author":"Wang","year":"2018","journal-title":"Int J Neuropsychopharmacol"},{"key":"key2025060220293600_ref44-bib44","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.bbi.2020.02.010","article-title":"Inflammatory markers in depression: a meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls","volume":"87","author":"Osimo","year":"2020","journal-title":"Brain Behav Immun"},{"key":"key2025060220293600_ref45-bib45","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.bbi.2020.04.013","article-title":"Chemokine alterations in bipolar disorder: a systematic review and meta-analysis","volume":"88","author":"Misiak","year":"2020","journal-title":"Brain Behav Immun"},{"key":"key2025060220293600_ref46-bib46","doi-asserted-by":"crossref","first-page":"pyw067","DOI":"10.1093\/ijnp\/pyw067","article-title":"Baseline perfusion alterations due to acute application of quetiapine and pramipexole in healthy adults","volume":"19","author":"Michels","year":"2016","journal-title":"Int J Neuropsychopharmacol"},{"key":"key2025060220293600_ref47-bib47","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch Gen Psychiatry"},{"key":"key2025060220293600_ref48-bib48","volume-title":"Paying the Price: The Cost of Mental Health Care in England to 2026","author":"McCrone","year":"2008"},{"key":"key2025060220293600_ref49-bib49","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.jad.2011.06.016","article-title":"Annual cost of managing bipolar disorder to the UK healthcare system","volume":"133","author":"Young","year":"2011","journal-title":"J Affect Disord"},{"key":"key2025060220293600_ref50-bib50","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/appi.ajp.2013.13070985","article-title":"Lurasidone as adjunctive therapy with lithium or valproate for the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am J Psychiatry"},{"key":"key2025060220293600_ref51-bib51","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study","volume":"171","author":"Loebel","year":"2014","journal-title":"Am J Psychiatry"},{"key":"key2025060220293600_ref52-bib52","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1017\/S1092852900000389","article-title":"A comparison of the QIDS-C16, QIDS-SR16, and the MADRS in an adult outpatient clinical sample","volume":"15","author":"Bernstein","year":"2010","journal-title":"CNS Spectr"},{"key":"key2025060220293600_ref53-bib53","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am J Psychiatry"},{"key":"key2025060220293600_ref54-bib54","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1176\/appi.ajp.2011.10111645","article-title":"Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study","volume":"168","author":"Rush","year":"2011","journal-title":"Am J Psychiatry"},{"key":"key2025060220293600_ref55-bib55","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/YIC.0b013e32834ce11b","article-title":"A pragmatic 12-week, randomized trial of duloxetine versus generic selective serotonin-reuptake inhibitors in the treatment of adult outpatients in a moderate-to-severe depressive episode","volume":"27","author":"Martinez","year":"2012","journal-title":"Int Clin Psychopharmacol"},{"key":"key2025060220293600_ref56-bib56","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1176\/appi.ajp.2015.14050680","article-title":"ABCB1 genetic effects on antidepressant outcomes: a report from the ISPOT-D trial","volume":"172","author":"Schatzberg","year":"2015","journal-title":"Am J Psychiatry"},{"key":"key2025060220293600_ref57-bib57","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1186\/s12888-021-03322-y","article-title":"Study protocol for a randomised placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment resistant bipolar depression (the PAX-BD study)","volume":"21","author":"Azim","year":"2021","journal-title":"BMC Psychiatry"},{"key":"key2025060220293600_ref58-bib58","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(09)61828-6","article-title":"Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial","volume":"375","author":"Geddes","year":"2010","journal-title":"Lancet"},{"key":"key2025060220293600_ref59-bib59","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S2215-0366(15)00450-2","article-title":"Comparative evaluation of quetiapine plus lamotrigine combination versus quetiapine monotherapy (and folic acid versus placebo) in bipolar depression (CEQUEL): a 2 \u00d7 2 factorial randomised trial","volume":"3","author":"Geddes","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"key2025060220293600_ref60-bib60","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/mds.24023","article-title":"Questionnaire for impulsive-compulsive disorders in Parkinson\u2019s Disease-Rating Scale","volume":"27","author":"Weintraub","year":"2012","journal-title":"Mov Disord"},{"key":"key2025060220293600_ref61-bib61","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jad.2021.07.035","article-title":"The meaningful change threshold as measured by the 16-item quick inventory of depressive symptomatology in adults with treatment-resistant major depressive and bipolar disorder receiving intravenous ketamine","volume":"294","author":"McIntyre","year":"2021","journal-title":"J Affect Disord"},{"key":"key2025060220293600_ref62-bib62","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/ijnp\/pyz011","article-title":"Prediction of acute-phase treatment outcomes by adding a single-item measure of activity impairment to symptom measurement: development and validation of an interactive calculator from the STAR*D and CO-MED trials","volume":"22","author":"Jha","year":"2019","journal-title":"Int J Neuropsychopharmacol"},{"key":"key2025060220293600_ref63-bib63","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"key2025060220293600_ref65-bib65","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"key2025060220293600_ref66-bib66","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"key":"key2025060220293600_ref67-bib67","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1192\/bjp.167.1.99","article-title":"A scale for the assessment of hedonic tone the Snaith\u2013Hamilton Pleasure Scale","volume":"167","author":"Snaith","year":"1995","journal-title":"Br J Psychiatry"},{"key":"key2025060220293600_ref68-bib68","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1192\/bjp.180.5.461","article-title":"The Work and Social Adjustment Scale: a simple measure of impairment in functioning","volume":"180","author":"Mundt","year":"2002","journal-title":"Br J Psychiatry"},{"key":"key2025060220293600_ref69-bib69","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S0006-3223(96)00548-3","article-title":"The Altman Self-Rating Mania Scale","volume":"42","author":"Altman","year":"1997","journal-title":"Biol Psychiatry"},{"key":"key2025060220293600_ref70-bib70","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bbr.2014.07.055","article-title":"Dopamine receptor D3 deficiency results in chronic depression and anxiety","volume":"274","author":"Moraga-Amaro","year":"2014","journal-title":"Behav Brain Res"},{"key":"key2025060220293600_ref71-bib71","doi-asserted-by":"crossref","first-page":"107597","DOI":"10.1016\/j.neuropharm.2019.04.003","article-title":"The highly selective dopamine D(3)R antagonist, R-VK4-40 attenuates oxycodone reward and augments analgesia in rodents","volume":"158","author":"Jordan","year":"2019","journal-title":"Neuropharmacology"},{"key":"key2025060220293600_ref72-bib72","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.biopsych.2020.02.017","article-title":"Midbrain D(3) receptor availability predicts escalation in cocaine self-administration","volume":"88","author":"Groman","year":"2020","journal-title":"Biol Psychiatry"},{"key":"key2025060220293600_ref73-bib73","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry"},{"key":"key2025060220293600_ref74-bib74","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br J Psychiatry"},{"key":"key2025060220293600_ref76-bib76","volume-title":"Data Protection Act 1998","author":"Jay","year":"1999"},{"key":"key2025060220293600_ref78-bib78","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"key2025060220293600_ref79-bib79","doi-asserted-by":"crossref","first-page":"e85287","DOI":"10.1371\/journal.pone.0085287","article-title":"A qualitative assessment of the content validity of the ICECAP-A and EQ-5D-5L and their appropriateness for use in health research","volume":"8","author":"Keeley","year":"2013","journal-title":"PLOS ONE"},{"key":"key2025060220293600_ref80-bib80","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12888-017-1211-8","article-title":"Assessing the validity of the ICECAP-A capability measure for adults with depression","volume":"17","author":"Mitchell","year":"2017","journal-title":"BMC Psychiatry"},{"key":"key2025060220293600_ref81-bib81","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1186\/s12955-017-0825-3","article-title":"Psychometric validation of a multi-dimensional capability instrument for outcome measurement in mental health research (OxCAP-MH)","volume":"15","author":"Vergunst","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"key2025060220293600_ref82-bib82","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.socscimed.2013.09.019","article-title":"Operationalising the capability approach for outcome measurement in mental health research","volume":"98","author":"Simon","year":"2013","journal-title":"Soc Sci Med"},{"key":"key2025060220293600_ref83-bib83","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jad.2014.10.005","article-title":"Factors affecting recruitment into depression trials: systematic review, meta-synthesis and conceptual framework","volume":"172","author":"Hughes-Morley","year":"2015","journal-title":"J Affect Disord"},{"key":"key2025060220293600_ref84-bib84","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1177\/02698811241309622","article-title":"A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study)","volume":"39","author":"McAllister-Williams","year":"2025","journal-title":"J Psychopharmacol"},{"key":"key2025060220293600_ref85-bib85","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1517\/14656566.2.12.1963","article-title":"Rapid cycling bipolar disorder","volume":"2","author":"Barrios","year":"2001","journal-title":"Expert Opin Pharmacother"},{"key":"key2025060220293600_ref86-bib86","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.4088\/JCP.v68n0810","article-title":"Pramipexole in psychiatry: a systematic review of the literature","volume":"68","author":"Aiken","year":"2007","journal-title":"J Clin Psychiatry"},{"key":"key2025060220293600_ref87-bib87","volume-title":"British National Formulary","author":"Joint Formulary Committee"},{"key":"key2025060220293600_ref88-bib88","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1017\/S0266462321001732","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"38","author":"Husereau","year":"2022","journal-title":"Int J Technol Assess Health Care"},{"key":"key2025060220293600_ref89-bib89","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198529446.001.0001","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2005"},{"key":"key2025060220293600_ref91-bib91","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00127-020-01919-4","article-title":"Cost and quality-of-life impacts of community treatment orders (CTOs) for patients with psychosis: economic evaluation of the OCTET trial","volume":"56","author":"Simon","year":"2021","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"key":"key2025060220293600_ref92-bib92","volume-title":"NICE Health Technology Evaluations: The Manual","author":"National Institute for Health and Care Excellence","year":"2022"},{"key":"key2025060220293600_ref93-bib93","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol \u2013 a new facility for the measurement of health-related quality of life","volume":"16","author":"Kasuya","year":"1990","journal-title":"Health Policy"},{"key":"key2025060220293600_ref94-bib94","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s11136-019-02393-5","article-title":"Capability instruments in economic evaluations of health-related interventions: a comparative review of the literature","volume":"29","author":"Helter","year":"2020","journal-title":"Qual Life Res"},{"key":"key2025060220293600_ref95-bib95","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1136\/ebmental-2021-300334","article-title":"Patient-reported outcome measures suitable for quality of life\/well-being assessment in multisectoral, multinational and multiperson mental health economic evaluations","volume":"25","author":"Laszewska","year":"2022","journal-title":"Evid Based Ment Health"},{"key":"key2025060220293600_ref96-bib96","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11136-011-9927-2","article-title":"Development of a self-report measure of capability wellbeing for adults: the ICECAP-A","volume":"21","author":"Al-Janabi","year":"2012","journal-title":"Qual Life Res"},{"key":"key2025060220293600_ref97-bib97","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/hec.3014","article-title":"Scoring the ICECAP-A capability instrument. Estimation of a UK general population tariff","volume":"24","author":"Flynn","year":"2015","journal-title":"Health Econ"},{"key":"key2025060220293600_ref98-bib98","volume-title":"HEQ (Health Economics Questionnaire)","author":"Simon","year":"2016"},{"key":"key2025060220293600_ref99-bib99","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1186\/s13063-017-2247-2","article-title":"The effects of using the PReDicT Test to guide the antidepressant treatment of depressed patients: study protocol for a randomised controlled trial","volume":"18","author":"Kingslake","year":"2017","journal-title":"Trials"},{"key":"key2025060220293600_ref101-bib101","author":"Hakkaart-van Roijen","year":"2002"},{"key":"key2025060220293600_ref102-bib102","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.healthpol.2005.07.016","article-title":"Cost-of-illness analysis. What room in health economics?","volume":"77","author":"Tarricone","year":"2006","journal-title":"Health Policy"},{"key":"key2025060220293600_ref104-bib104","volume-title":"Unit Costs of Health and Social Care 2021","author":"Jones","year":"2021"},{"key":"key2025060220293600_ref105-bib105","doi-asserted-by":"crossref","DOI":"10.1002\/9781119013563","volume-title":"Statistical Analysis with Missing Data: Little\/Statistical Analysis with Missing Data","author":"Little","year":"2002"},{"key":"key2025060220293600_ref106-bib106","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"key2025060220293600_ref107-bib107","doi-asserted-by":"crossref","DOI":"10.1201\/9780429246593","volume-title":"An Introduction to the Bootstrap","author":"Efron","year":"1994"},{"key":"key2025060220293600_ref108-bib108","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1192\/bjp.187.2.106","article-title":"A guide to cost-effectiveness acceptability curves","volume":"187","author":"Fenwick","year":"2005","journal-title":"Br J Psychiatry"},{"key":"key2025060220293600_ref109-bib109","doi-asserted-by":"crossref","first-page":"S68","DOI":"10.1177\/0272989X98018002S09","article-title":"Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis","volume":"18","author":"Stinnett","year":"1998","journal-title":"Med Decis Making"},{"key":"key2025060220293600_ref110-bib110","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S2215-0366(20)30516-2","article-title":"Reconceptualising treatment-resistant depression as difficult-to-treat depression","volume":"8","author":"McAllister-Williams","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"key2025060220293600_ref111-bib111","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1111\/ene.13034","article-title":"A European multicentre survey of impulse control behaviours in Parkinson\u2019s disease patients treated with short- and long-acting dopamine agonists","volume":"23","author":"Rizos","year":"2016","journal-title":"Eur J Neurol"},{"key":"key2025060220293600_ref112-bib112","doi-asserted-by":"crossref","first-page":"105109","DOI":"10.1016\/j.neubiorev.2023.105109","article-title":"Neural correlates of impulsivity in bipolar disorder: a systematic review and clinical implications","volume":"147","author":"Chan","year":"2023","journal-title":"Neurosci Biobehav Rev"},{"key":"key2025060220293600_ref113-bib113","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.pnpbp.2019.01.017","article-title":"Modulation of stress- and cocaine prime-induced reinstatement of conditioned place preference after memory extinction through dopamine D3 receptor","volume":"92","author":"Guerrero-Bautista","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"key2025060220293600_ref114-bib114","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.phrs.2019.01.022","article-title":"Dopaminergic-GABAergic interplay and alcohol binge drinking","volume":"141","author":"Leggio","year":"2019","journal-title":"Pharmacol Res"},{"key":"key2025060220293600_ref115-bib115","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1093\/brain\/awaa002","article-title":"Baseline reward processing and ventrostriatal dopamine function are associated with pramipexole response in depression","volume":"143","author":"Whitton","year":"2020","journal-title":"Brain"},{"key":"key2025060220293600_ref116-bib116","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush","year":"2003","journal-title":"Biol Psychiatry"},{"key":"key2025060220293600_ref117-bib117","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jad.2006.03.024","article-title":"Making clinicians lives easier: guidance on use of the QIDS self-report in place of the MADRS","volume":"95","author":"Carmody","year":"2006","journal-title":"J Affect Disord"},{"key":"key2025060220293600_ref118-bib118","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.euroneuro.2022.01.113","article-title":"Impulse control disorders associated with dopaminergic drugs: a disproportionality analysis using vigibase","volume":"58","author":"De Wit","year":"2022","journal-title":"Eur Neuropsychopharmacol"},{"key":"key2025060220293600_ref119-bib119","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14740338.2017.1379989","article-title":"Lurasidone: efficacy and safety in the treatment of psychotic and mood disorders","volume":"17","author":"Pompili","year":"2018","journal-title":"Expert Opin Drug Saf"},{"key":"key2025060220293600_ref120-bib120","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/da.22479","article-title":"Lurasidone in the long\u2010term treatment of patients with bipolar disorder: a 24\u2010week open\u2010label extension study","volume":"33","author":"Ketter","year":"2016","journal-title":"Depress Anxiety"},{"key":"key2025060220293600_ref121-bib121","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1192\/bjp.2019.36","article-title":"Treatment-resistant and multi-therapy resistant criteria for bipolar depression: consensus definition \u2013 CORRIGENDUM","volume":"214","author":"Hidalgo-Mazzei","year":"2019","journal-title":"Br J Psychiatry"},{"key":"key2025060220293600_ref122-bib122","first-page":"374","article-title":"The value of computer-administered self-report data in central nervous system clinical trials","volume":"8","author":"Byrom","year":"2005","journal-title":"Curr Opin Drug Discov Devel"},{"key":"key2025060220293600_ref123-bib123","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.biopsych.2005.05.025","article-title":"Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial","volume":"58","author":"Rush","year":"2005","journal-title":"Biol Psychiatry"},{"key":"key2025060220293600_ref124-bib124","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.3399\/bjgp16X683437","article-title":"Unrecognised bipolar disorder among UK primary care patients prescribed antidepressants: an observational study","volume":"66","author":"Hughes","year":"2016","journal-title":"Br J Gen Pract"},{"key":"key2025060220293600_ref125-bib125","volume-title":"ReseArch with Patient and Public invOlvement: a RealisT evaluation \u2013 the RAPPORT study","author":"Wilson","year":"2015"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2048010","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/sites\/journalslibrary\/files\/journal_data\/HBFC1953\/HBFC1953.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2048010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T11:07:21Z","timestamp":1748862441000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/HBFC1953"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":118,"alternative-id":["10.3310\/HBFC1953"],"URL":"https:\/\/doi.org\/10.3310\/hbfc1953","relation":{},"ISSN":["2046-4924"],"issn-type":[{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"04-2018","name":"contractual_start_date","label":"contractual_start_date","group":{"name":"article_history","label":"Article History"}},{"value":"06-2023","name":"editorial_review_begun","label":"editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"08-2024","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}